Amyloid-beta transporter expression at the blood-CSF barrier is age-dependent

Fluids and Barriers of the CNS

Gerald D Silverberg¹  Conrad E Johanson¹  Liliana Gonzalez²  Ilias N Caralopoulos¹  Matthew Boylan¹  Catherine Chiu¹  Miles C Miller¹  Crissey L Pascale¹ 

[1] Warren Alpert Medical School Brown University, RI Hospital Department of Neurosurgery 593 Eddy St. Providence, RI 02903 USA;University of Rhode Island Department of Computer Science and Statistics Kingston, RI 02881 USA

关键词: RAGE;    P-gp;    LRP -2;    LRP-1;    blood-CSF-barrier;    choroid plexus;    transport;    amyloid-beta;    aging;   

Others  :  807418
DOI  :  10.1186/2045-8118-8-21

 received in 2011-03-17, accepted in 2011-07-08,  发布年份 2011

【 摘 要 】

Background

Age is the major risk factor for many neurodegenerative diseases, including Alzheimer's disease (AD). There is an accumulation of amyloid-beta peptides (Aβ) in both the AD brain and the normal aging brain. Clearance of Aβ from the brain occurs via active transport at the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). With increasing age, the expression of the Aβ efflux transporters is decreased and the Aβ influx transporter expression is increased at the BBB, adding to the amyloid burden in the brain. Expression of the Aβ transporters at the choroid plexus (CP) epithelium as a function of aging was the subject of this study.

Methods

This project investigated the changes in expression of the Aβ transporters, the low density lipoprotein receptor-related protein-1 (LRP-1), P-glycoprotein (P-gp), LRP-2 (megalin) and the receptor for advanced glycation end-products (RAGE) at the BCSFB in Brown-Norway/Fischer rats at ages 3, 6, 9, 12, 20, 30 and 36 months, using real time RT-PCR to measure transporter mRNA expression, and immunohistochemistry (IHC) to measure transporter protein in isolated rat CP.

Results

There was an increase in the transcription of the Aβ efflux transporters, LRP-1 and P-gp, no change in RAGE expression and a decrease in LRP-2, the CP epithelium influx transporter, at the BCSFB with aging. Decreased Aβ42 concentration in the CP, as measured by quantitative IHC, was associated with these Aβ transporter alterations.

Conclusions

Age-dependent alterations in the CP Aβ transporters are associated with a decrease in Aβ42 accumulation in the CP, and are reciprocal to the changes seen in these transporters at the BBB, suggesting a possible compensatory role for the BCSFB in Aβ clearance in aging.

【 授权许可】

   
2011 Pascale et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Hardy J: A hundred years of Alzheimer's disease research. Neuron 2006, 52:3-13.
• [2]Querfurth HW, LaFerla FM: Alzheimer's disease. N Eng J Med 2010, 362:329-344.
• [3]Yankner BA, Lu T: Amyloid beta-protein toxicity and the pathogenesis of Alzheimer disease. J Biol Chem 2009, 284:4755-4759.
• [4]Selkoe DJ: Toward a comprehensive theory for Alzheimer's disease. Hypothesis: Alzheimer's disease is caused by the cerebral accumulation and cytotoxicity of amyloid beta-protein. Ann NY Acad Sci 2000, 924:17-25.
• [5]Silverberg GD, Miller MC, Messier AA, Majmudar S, Machan JT, Donahue JE, Stopa EG, Johanson CE: Amyloid deposition and influx transporter expression at the blood-brain barrier increase in normal aging. J Neuropathol Exp Neurol 2010, 69:98-108.
• [6]Yankner BA, Lu T, Loerch P: The aging brain. Ann Rev Pathol 2008, 3:41-66.
• [7]Rubenstein E: Relationship of senescence of cerebrospinal fluid circulatory system to dementias of the aged. Lancet 1998, 351:283-285.
• [8]Mawuenyega KG, Sigurdson W, Ovod V, Munselli T, Kasten T, Morris JC, Yarasheski KE, Bateman RJ: Decreased Clearance of CNS β-Amyloid in Alzheimer's Disease. Science 2010, 330:1774.
• [9]Silverberg GD, Messier AA, Miller MC, Machan JT, Majmudar S, Stopa EG, Donahue JE, Johanson CE: Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging. J Neuropathol Exp Neurol 2010, 69:1034-1043.
• [10]Donahue JE, Flaherty SL, Johanson CE, Duncan JA, Silverberg GD, Miller MC, Tavares R, Yang W, Wu Q, Sabo E, Hovanesian V, Stopa EG: RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease. Acta Neuropathol (Berl) 2006, 11:405-415.
• [11]Deane R, Zlokovic BV: Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2007, 4:191-197.
• [12]Miller MC, Tavares R, Johanson CE, Hovanesian V, Donahue JE, Gonzalez L, Silverberg GD, Stopa EG: Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease. Brain Res 2008, 1230:273-280.
• [13]Preston JE: Ageing choroid plexus-cerebrospinal fluid system. Microsc Res Tech 2001, 52:31-37.
• [14]Silverberg GD, Mayo M, Saul T, Rubenstein E, McGuire D: Alzheimer's disease, normal-pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis. Lancet Neurol 2003, 2:506-511.
• [15]Tanzi RE, Moir RD, Wagner SL: Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 2004, 43:605-608.
• [16]Zlokovic BV: Clearing amyloid through the blood-brain barrier. J Neurochem 2004, 89:807-811.
• [17]Hartz AM, Miller DS, Bauer B: Restoring blood-brain barrier P-glycoprotein reduces brain A{beta} in a mouse model of Alzheimer's disease. Mol Pharmacol 2010, 77:715-723.
• [18]Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV: Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest 2000, 106:1489-1499.
• [19]Deane R, Du Yan S, Submamaryan RK, LaRue B, Jovanovic S, Hogg E, Welch D, Manness L, Lin C, Yu J, Zhu H, Ghiso J, Frangione B, Stern A, Schmidt AM, Armstrong DL, Arnold B, Liliensiek B, Nawroth P, Hofman F, Kindy M, Stern D, Zlokovic B: RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med 2003, 9:907-913.
• [20]Lu T, Pan Y, Kao S, Li C, Kohane I, Chan J, Yankner BA: Gene regulation and DNA damage in the ageing human brain. Nature 2004, 429:883-891.
• [21]May C, Kaye JA, Atack JR, Schapiro MB, Friedland RP, Rapoport SI: Cerebrospinal fluid production is reduced in healthy aging. Neurology 1990, 40:500-503.
• [22]Silverberg GD, Miller MC, Machan JT, Johanson CE, Caralopoulos IN, Pascale CL, Heile A, Klinge PM: Amyloid and Tau accumulate in the brains of aged hydrocephalic rats. Brain Res 2010, 1317:286-296.
• [23]Silverberg GD, Heit G, Huhn S, Jaffe RA, Chang SD, Bronte-Stewart H, Rubenstein E, Possin K, Saul TA: The cerebrospinal fluid production rate is reduced in dementia of the Alzheimer's type. Neurology 2001, 57:1763-1766.
• [24]Silverberg GD, Huhn S, Jaffe RA, Chang SD, Saul T, Heit G, Von Essen A, Rubenstein E: Downregulation of cerebrospinal fluid production in patients with chronic hydrocephalus. J Neurosurg 2002, 97:1271-1275.
• [25]Johanson CE, Duncan JA, Stopa EG, Baird A: Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route. Pharmaceut Res 2005, 22:1011-1037.
• [26]Spector R, Johanson CE: Vectorial ligand transport through mammalian choroid plexus. Pharm Res 2010, 27:2054-2062.
• [27]Behl M, Zhang Y, Monnot AD, Jiang W, Zheng W: Increased beta-amyloid levels in the choroid plexus following lead exposure and the involvement of low-density lipoprotein receptor protein-1. Toxicol Appl Pharmacol 2009, 240:245-254.
• [28]de Lange EC: Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. Adv Drug Deliv Rev 2004, 56:1793-1809.
• [29]Hammad SM, Ranganathan S, Loukinova E, Twal WO, Argraves WS: Interaction of apolipoprotein J-amyloid beta-peptide complex with low density lipoprotein receptor-related protein-2/megalin. A mechanism to prevent pathological accumulation of amyloid beta-peptide. J Biol Chem 1997, 272:18644-18649.
• [30]Hoffman WH, Artlett CM, Zhang W, Kreipke CW, Passmore GG, Rafols JA, Sima AA: Receptor for advanced glycation end products and neuronal deficit in the fatal brain edema of diabetic ketoacidosis. Brain Res 2008, 1238:154-162.
• [31]Haass C, Selkoe DJ: Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat Rev Mol Cell Biol 2007, 8:101-112.
• [32]Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM: Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 2005, 26:645-654.
• [33]Crossgrove JS, Smith EL, Zheng W: Macromolecules involved in production and metabolism of beta-amyloid at the brain barriers. Brain Res 2007, 1138:187-195.
• [34]Emerich DF, Skinner SJM, Borlongan CV, Vasconcellos AV, Thanos CG: The choroid plexus in the rise, fall and repair of the brain. Bioessays 2005, 27:262-274.
• [35]Smith DE, Johanson CE, Keep RF: Peptide and peptide analog transport systems at the blood-CSF barrier. Adv Drug Deliv Rev 2004, 56:1765-1791.
• [36]Johanson C, Stopa E, Baird A, Sharma H: Traumatic brain injury and recovery mechanisms: Peptide modulation of periventricular neurogenic regions by the choroid plexus-CSF nexus. J Neural Transm 2011, 118:115-133.
• [37]Serot J, Béné M, Faure GC: Choroid plexus, aging of the brain, and Alzheimer's disease. Front Biosci 2003, 8(suppl):s515-521.
• [38]Johanson C, McMillan P, Tavares R, Spangenberger A, Duncan J, Silverberg G, Stopa E: Homeostatic capabilities of the choroid plexus epithelium in Alzheimer's disease. Cerebrospinal Fluid Res 2004, 1:3. BioMed Central Full Text
• [39]Alvira-Botero X, Carro EM: Clearance of amyloid-peptide across the choroid plexus in Alzheimer's disease. Curr Aging Sc 2010, 3:219-229.
• [40]Vargas T, Ugalde C, Spuch C, Antequera D, Morán MJ, Martín MA, Ferrer I, Bermejo-Pareja F, Carro E: Abeta accumulation in choroid plexus is associated with mitochondrial-induced apoptosis. Neurobiol Aging 2008, 31:1569-1581.
• [41]Segal MB: The choroid plexuses and the barriers between the blood and the cerebrospinal fluid. Cell Mol Neurobiol 2000, 20:183-196.
• [42]Herz J, Bock HH: Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002, 71:405-434.
• [43]Lillis AP, Van Duyn LB, Murphy-Ullrich JE, Strickland DK: LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008, 88:887-918.
• [44]Harris-White ME, Frautschy SA: Low density lipoprotein receptor-related proteins (LRPs), Alzheimer's and cognition. Curr Drug Targets CNS Neurol Disord 2005, 4:469-480.
• [45]Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncosco JC, Kawas CH, Katzman R, Koo EH: Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 2000, 106:1159-1166.
• [46]Jaeger S, Pietrzik CU: Functional role of lipoprotein receptors in Alzheimer's disease. Curr Alzheimer Res 2008, 5:15-25.
• [47]Liu Q, Zhang J, Tran H, Verbeek MM, Reiss K, Estus S, Bu G: LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Mol Neurodegener 2009, 4:17. BioMed Central Full Text
• [48]Chun JT, Wang L, Pasinetti GM, Finch CE, Zlokovic BV: Glycoprotein 330/megalin (LRP-2) has low prevalence as mRNA and protein in brain microvessels and choroid plexus. Exp Neurol 1999, 157:194-201.
• [49]Carro E, Spuch C, Trejo JL, Antequera D, Torres-Aleman I: Choroid plexus megalin is involved in neuroprotection by serum insulin-like growth factor I. J Neurosci 2005, 25:10884-10893.
• [50]Dietrich MO, Spuch C, Antequera D, Rodal I, de Yébenes JG, Molina JA, Bermejo F, Carro E: Megalin mediates the transport of leptin across the blood-CSF barrier. Neurobiol Aging 2008, 29:902-912.
• [51]Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J: Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci USA 1996, 93:4229-4234.
• [52]Sharom FJ: Shedding light on drug transport: structure and function of the P-glycoprotein multidrug transporter (ABCB1). Biochem Cell Biol 2006, 84:979-992.
• [53]Rao VV, Dahlheimer JL, Bardgett ME, Snyder AZ, Finch RA, Sartorelli AC, Piwnica-Worms D: Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Nat Acad Sci USA 1999, 96:3900-3905.
• [54]Srikanth V, Maczurek A, Phan T, Steele M, Westcott B, Juskiw D, Münch G: Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease. Neurobiol Aging 2011, 32:763-777.
• [55]Chen X, Walker DG, Schmidt AM, Arancio O, Lue L, Yan SD: RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007, 7:735-742.
• [56]Li M, Shang D, Zhao W, Tian L, Li B, Fang W, Zhu L, Man SM, Chen YH: Amyloid beta interaction with receptor for advanced glycation end products up-regulates brain endothelial CCR5 expression and promotes T cells crossing the blood-brain barrier. J Immunol 2009, 182:5778-5788.
• [57]Serot J, Christmann D, Dubost T, Couturier M: Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1997, 63:506-508.